Abstract
(-)-(cis)-4-(2-Amino-9H-purin-9-yl)-2-cyclopentenyl carbinol (6-deoxycarbovir) was prepared in order to evaluate prodrug approaches to increased bioavailability of the anti-HIV agent, (-)-carbovir. Incubation experiments demonstrated that 6-deoxycarbovir was rapidly converted to (-)-carbovir by the enzyme, xanthine oxidase. Since xanthine oxidase activity is present in both the intestine and liver, a high first pass conversion to carbovir would be expected in vivo.
Original language | English (US) |
---|---|
Pages (from-to) | 39-44 |
Number of pages | 6 |
Journal | Nucleosides and Nucleotides |
Volume | 14 |
Issue number | 1-2 |
DOIs | |
State | Published - Feb 1 1995 |
Bibliographical note
Funding Information:Acknowledgment. This work was supported by Public Health Service Grant CA23263 from the National Cancer Institute.